| Literature DB >> 34277469 |
Yali Gong1,2, Yuan Peng3, Xiaoqiang Luo1,2, Cheng Zhang1,2, Yunlong Shi1,2, Yixin Zhang3, Jun Deng1,2, Yizhi Peng1,2, Gaoxing Luo1,2, Haisheng Li1,2.
Abstract
Infection is the leading cause of complications and deaths after burns. However, the difference in infection patterns between the burn intensive care unit (BICU) and burn common wards (BCW) have not been clearly investigated. The present study aimed to compare the infection profile, antimicrobial resistance, and their changing patterns in burn patients in BICU and BCW. Clinical samples were analyzed between January 1, 2011, and December 31, 2019, in the Institute of Burn Research in Southwest China. The patient information, pathogen distribution, sources, and antimicrobial resistance were retrospectively collected. A total of 3457 and 4219 strains were detected in BICU and BCW, respectively. Wound secretions accounted for 86.6% and 44.9% in BCW and BICU, respectively. Compared with samples in BCW, samples in BICU had more fungi (11.8% vs. 8.1%), more Gram-negative bacteria (60.0% vs. 50.8%), and less Gram-positive bacteria (28.2% vs. 41.1%). Acinetobacter baumannii were the most common pathogen in BICU, compared with Staphylococcus aureus in BCW. S. aureus was the most frequent pathogen in wound secretions and tissues from both BICU and BCW. However, A. baumannii were the first in blood, sputum, and catheter samples from BICU. Overall, the multidrug-resistance (MDR) rate was higher in BICU than in BCW. However, the gap between BICU and BCW gradually shortened from 2011 to 2019. The prevalence of MDR A. baumannii and Klebsiella pneumonia significantly increased, especially in BCW. Furthermore, Carbapenem resistance among K. pneumoniae significantly increased in BICU (4.5% in 2011 vs. 40% in 2019) and BCW (0 in 2011 vs. 40% in 2019). However, the percentage of MDR P. aeruginosa sharply dropped from 85.7% to 24.5% in BICU. The incidence of MRSA was significantly higher in BICU than in BCW (94.2% vs. 71.0%) and stayed at a high level in BICU (89.5% to 96.3%). C. tropicalis and C. albicans were the two most frequent fungi. No resistance to Amphotericin B was detected. Our study shows that the infection profile is different between BICU and BCW, and multidrug resistance is more serious in BICU than BCW. Therefore, different infection-control strategies should be emphasized in different burn populations.Entities:
Keywords: antimicrobial resistance; burn infection; carbapenem-resistant Gram-negative bacteria; fungi; methicillin-resistant Staphylococcus aureus; multi-drug resistance
Mesh:
Substances:
Year: 2021 PMID: 34277469 PMCID: PMC8278283 DOI: 10.3389/fcimb.2021.681731
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Clinical feature of burn patients in BICU and BCW.
| BICU | BCW | |
|---|---|---|
|
| 1159 | 14,379 |
|
| 23,717 | 22,672 |
|
| 3457 | 4219 |
|
| 43.8 ± 23.2* | 28. 3 ± 22.8 |
|
| ||
| Males (n, %) | 735 (63.4) | 9284 (64.6) |
| Females (n, %) | 424 (36.6) | 5095 (35.4) |
|
| ||
| Flame (n, %) | 607 (52.4) | 2062 (14.3) |
| Scald (n, %) | 289 (24.9) | 5279 (36.7) |
| Electrical burns (n, %) | 95 (8.2) | 1624 (11.3) |
| Others (n, %) | 168 (14.5) | 5414 (37.7) |
|
| 58.9 ± 12.3* | 13.7 ± 7.3 |
*P <.001 compared with patients in BCW.
Figure 1Pathogen sources in BICU and BCW. (A) Pathogen sources in BICU. (B) Pathogen sources in BCW. (C) The annual kinetics of pathogen sources in BICU. (D) The annual kinetics of pathogen sources in BCW.
Pathogen distributions among different types of clinical samples.
| Pathogens | Wounds (%) | Blood (%) | Sputum (%) | Catheters (%) | Urine (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BICU( | BCW ( | BICU( | BCW ( | BICU( | BCW ( | BICU( | BCW ( | BICU( | BCW ( | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 23.0 | 26.8 | 13.8 | 19.4 | 13.6 | 15.4 | 17.1 | 52.4 | 1.7 | 0.0 |
|
| 3.5 | 3.5 | 1.7 | 9.0 | 0.2 | 2.2 | 2.7 | 4.8 | 1.2 | 0.0 |
|
| 2.7 | 2.8 | 3.7 | 4.5 | 0.3 | 2.2 | 1.8 | 1.2 | 4.0 | 14.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 15.6 | 6.7 | 24.7 | 9.0 | 26.1 | 13.2 | 23.8 | 11.9 | 6.9 | 5.1 |
|
| 14.3 | 15.4 | 12.6 | 9.0 | 13.6 | 14.3 | 22.3 | 14.3 | 13.3 | 12.8 |
|
| 5.8 | 4.4 | 5.5 | 3.0 | 9.9 | 8.8 | 6.4 | 1.2 | 9.2 | 9.0 |
|
| 4.4 | 5.4 | 4.4 | 3.0 | 1.7 | 4.4 | 2.4 | 0.0 | 0.6 | 1.3 |
|
| 5.8 | 6.5 | 1.7 | 3.0 | 1.6 | 0.0 | 3.0 | 1.2 | 7.5 | 15.4 |
|
| 2.9 | 1.5 | 3.0 | 0.0 | 4.5 | 0.0 | 2.1 | 0.0 | 0.0 | 2.6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1.6 | 0.9 | 1.2 | 7.5 | 7.0 | 12.1 | 2.1 | 3.6 | 9.2 | 7.7 |
|
| 1.5 | 1.0 | 1.2 | 0.0 | 3.3 | 1.1 | 2.1 | 4.8 | 16.2 | 6.4 |
|
| 1.0 | 0.9 | 2.9 | 3.0 | 0.8 | 0.0 | 4.3 | 3.6 | 8.7 | 5.1 |
|
| 0.4 | 0.5 | 1.0 | 0.0 | 1.9 | 4.4 | 1.5 | 0.0 | 10.4 | 0.0 |
BICU, Burn intensive care units; BCW, burn common wards.
The bold values mean the percentage of Gram+ bacteria, Gram- bacteria and fungi of all the pathogens in different clinical samples.
Figure 2Pathogen types in BICU and BCW. (A) The composition of different type of pathogens. (B) The changes of pathogen composition in BICU during 2011 to 2019. (C) The changes of pathogen composition in BCW during 2011 to 2019.
Figure 3Main pathogens in BICU and BCW. Changes of the five most common pathogens in BICU (A) and BCW (B).
Figure 4Annual changes of MDR of common bacteria. (A) Annual distribution of MDR of Acinetobacter baumannii from BICU and BCW. (B) Annual distribution of MDR of Pseudomonas aeruginosa from BICU and BCW. (C) Annual distribution of MDR of Klebsiella pneumonia from BICU and BCW. (D) Annual distribution of MDR of MRSA from BICU and BCW.
Antimicrobial resistance of Gram-negative bacteria in BICU and BCW.
| Pathogens |
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BICU( | BCW ( | BICU( | BCW ( | BICU( | BCW ( | BICU( | BCW ( | BICU( | BCW ( | |
| Ampicillin | ND | ND | ND | ND | 98.7 | 97.4 | 86.5 | 87.5 | 94.3 | 88.9 |
| Piperacillin | 94.0 | 74.9 | 55.5 | 15.0 | 83.3 | 53.7 | 67.0 | 36.1 | 84.0 | 84.7 |
| Amoxicillin/clavulanate | ND | ND | ND | ND | 77.9 | 30.0 | 91.3 | 95.7 | 70.5 | 34.8 |
| Cefoperazone/Subactam | 80.1 | 61.0 | 42.7 | 18.3 | 29.4 | 14.7 | 21.9 | 4.6 | 2.9 | 5.4 |
| Ampicillin/sulbactam | 90.5 | 69.8 | ND | ND | 76.4 | 46.9 | 82.6 | 77.0 | 63.2 | 60.0 |
| Piperacillin/tazobactam | 92.7 | 71.3 | 34.7 | 11.5 | 35.1 | 12.7 | 28.9 | 10.7 | 7.4 | 11.6 |
| Cefoperazone | ND | ND | ND | ND | 74.0 | 45.9 | 55.7 | 26.2 | 76.6 | 65.6 |
| Cefuroxime | ND | ND | ND | ND | 78.3 | 51.1 | 73.9 | 64.8 | 77.3 | 65.7 |
| Ceftazidime | 91.6 | 72.7 | 37.6 | 18.3 | 51.9 | 23.9 | 60.8 | 26.6 | 47.8 | 38.6 |
| Ceftriaxone | 95.0 | 84.1 | ND | ND | 70.8 | 70.0 | 31.8 | 28.6 | 79.5 | 62.7 |
| Cefotaxime | 93.4 | 80.5 | 98.6 | 97.1 | 77.1 | 50.0 | 69.1 | 36.1 | 78.7 | 64.6 |
| Cefepime | 93.2 | 72.5 | 39.4 | 15.0 | 58.9 | 38.2 | 48.9 | 19.1 | 75.0 | 52.5 |
| Aztreonam | 99.5 | 98.7 | 38.4 | 25.9 | 62.2 | 38.9 | 22.7 | 29.2 | 50.0 | 53.6 |
| Imipenem | 93.2 | 58.2 | 42.3 | 12.4 | 22.7 | 2.3 | 8.8 | 0.6 | 2.5 | 2.2 |
| Amikacin | 87.5 | 68.9 | 37.4 | 7.4 | 36.4 | 14.5 | 25.2 | 11.7 | 19.3 | 19.9 |
| Gentamicin | 92.1 | 73.1 | 42.5 | 13.5 | 64.0 | 35.4 | 42.3 | 23.0 | 64.8 | 53.0 |
| Tobramycin | 90.7 | 71.4 | 49.8 | 11.1 | 58.5 | 36.6 | 42.8 | 31.5 | 63.6 | 25.4 |
| Ciprofloxacin | 93.7 | 70.7 | 25.8 | 8.3 | 57.3 | 33.6 | 25.8 | 13.0 | 65.9 | 59.7 |
| Levofloxacin | 89.5 | 45.5 | 35.5 | 7.9 | 40.9 | 17.6 | 14.9 | 8.0 | 65.9 | 55.8 |
| SMZ-TMP | 89.0 | 69.2 | 99.1 | 99.0 | 71.6 | 50.4 | 49.4 | 37.7 | 78.4 | 58.2 |
| Polymyxin B | 0 | 0 | 0 | 0 | ND | ND | ND | ND | ND | ND |
| Tigecycline | 0 | 0 | ND | ND | 0 | 0 | 0 | 0 | 0 | 0 |
BICU, Burn intensive care units; BCW, burn common wards; ND, Not done.
Figure 5Annual changes of antibacterial resistance of main Gram-negative bacteria. (A) Annual distribution of antibacterial resistance of Acinetobacter baumannii from burn ICU (left) and common ward (right). (B) Annual distribution of antibacterial resistance of Pseudomonas aeruginosa from burn ICU (left) and common ward (right). (C) Annual distribution of antibacterial resistance of Klebsiella pneumonia from burn ICU (left) and common ward (right).
Antimicrobial resistance of Gram-positive bacteria in BICU and BCW.
| Pathogens |
|
|
| |||
|---|---|---|---|---|---|---|
| BICU ( | BCW ( | BICU ( | BCW ( | BICU ( | BCW ( | |
| Ampicillin | ND | ND | ND | ND | 80.0 | 63.2 |
| Penicillin | 100 | 98.0 | 100 | 100 | ND | ND |
| Oxacillin | 94.2 | 71.0 | 94.1 | 98.2 | ND | ND |
| Gentamycin (120 ug)# | ND | ND | ND | ND | 55.0 | 50.0 |
| Gentamycin (10 ug) | 94.4 | 65.3 | 82.4 | 79.3 | ND | ND |
| Rifampicin | 93.4 | 57.0 | 31.7 | 30.6 | 89.1 | 71.1 |
| Ciprofloxacin | 94.4 | 95.4 | 93.3 | 87.4 | 80.0 | 47.4 |
| Levofloxacin | 94.4 | 59.0 | 94.1 | 96.7 | 75.0 | 66.7 |
| Moxifloxacin | 93.9 | 57.6 | 94.1 | 63.3 | 80.0 | 83.3 |
| Ofloxacin | 94.2 | 64.1 | 93.3 | 88.3 | ND | ND |
| SMZ-TMP | 2.3 | 9.3 | 61.7 | 51.7 | ND | ND |
| Clindamycin | 18.1 | 47.3 | 53.8 | 76.9 | ND | ND |
| Erythromycin | 49.6 | 75.1 | 93.3 | 96.4 | 94.4 | 84.2 |
| Linezolid | 0 | 0 | 0 | 0 | 0 | 0 |
| Vancomycin | 0 | 0 | 0 | 0 | 0 | 0 |
| Teicoplanin | 0 | 0 | 0 | 0 | 0 | 0 |
| Tigecycline | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloramphenicol | 78.7 | 49.6 | 30.0 | 27.9 | 1.8 | 7.9 |
| Quinuptin/Dafoptin | 82.0 | 52.7 | 14.3 | 7.7 | ND | ND |
| Tetracycline | 95.8 | 67.5 | 52.9 | 37.9 | 61.8 | 16.7 |
| Minocyline | ND | ND | ND | ND | 40.0 | 44.7 |
BICU, Burn intensive care units; BCW, burn common wards; ND, Not done. #: High-level gentamicin was only used in sensitivity analysis of genus enterococcus to predict the synergistic effects of aminoglycoside antibiotics combined with ampicillin, penicillin, or vancomycin as indicated in CLSI M100.
Figure 6Annual changes of antibacterial resistance of main Gram-positive bacteria. (A) Annual distribution of antibacterial resistance of Staphylococcus aureus from burn ICU (left) and common ward (right). (B) Annual distribution of antibacterial resistance of Staphylococcus haemolyticus from burn ICU (left) and common ward (right). (C) Annual distribution of antibacterial resistance of Enterococcus faecium from burn ICU (left) and common ward (right).
The resistance of common fungi to antifungal drugs.
| Pathogens |
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|
| BICU ( | BCW ( | BICU ( | BCW ( | BICU ( | BCW ( | BICU ( | BCW ( | |
| Voriconazole | 1 | 0 | 13.7 | 5.3 | 1.1 | 2.4 | 4.5 | 0 |
| Amphotericin B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-Fluorocytosine | 4.8 | 0 | 0 | 0 | 2.4 | 0 | 50.0 | 47.9 |
| Fluconazole | 0 | 1.7 | 19.2 | 10.5 | 0 | 0 | 63.0 | 48.2 |
| Itracoazole | 0 | 0 | 10.7 | 5.3 | 0 | 0 | 54.5 | 33.3 |
| Ketoconazole | 2.7 | 0 | 3.2 | 0 | 0 | 0 | 28.7 | 16.8 |
BICU, Burn intensive care units; BCW, burn common wards.